Literature DB >> 21389249

Update on medications with adverse skeletal effects.

Caroline J Davidge Pitts1, Ann E Kearns.   

Abstract

Patients rely on their primary care physician to manage multiple, often chronic medical conditions that require prescription medications. Balancing the risk to benefit of treatments can be challenging and requires that the primary care physician stay abreast of new information regarding risks and benefits. The number of medications with reported adverse effects on skeletal health is expanding. This review focuses on medications recently added to the list of "bad to the bone" drugs and on recent advances in management of glucocorticoid-induced osteoporosis. A practical approach to assessing and managing the skeletal risks is outlined.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21389249      PMCID: PMC3068894          DOI: 10.4065/mcp.2010.0636

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  44 in total

Review 1.  American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  Jennifer M Grossman; Rebecca Gordon; Veena K Ranganath; Chad Deal; Liron Caplan; Weiling Chen; Jeffrey R Curtis; Daniel E Furst; Maureen McMahon; Nivedita M Patkar; Elizabeth Volkmann; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07-26       Impact factor: 4.794

2.  Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.

Authors:  S A Stoch; R A Parker; L Chen; G Bubley; Y J Ko; A Vincelette; S L Greenspan
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

3.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Authors:  M R Smith; F J McGovern; A L Zietman; M A Fallon; D L Hayden; D A Schoenfeld; P W Kantoff; J S Finkelstein
Journal:  N Engl J Med       Date:  2001-09-27       Impact factor: 91.245

4.  Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women.

Authors:  Hassan M Heshmati; Sundeep Khosla; Simon P Robins; W Michael O'Fallon; L Joseph Melton; B Lawrence Riggs
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

5.  An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium.

Authors:  G W Bo-Linn; G R Davis; D J Buddrus; S G Morawski; C Santa Ana; J S Fordtran
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

Review 6.  Sex steroids and the construction and conservation of the adult skeleton.

Authors:  B Lawrence Riggs; Sundeep Khosla; L Joseph Melton
Journal:  Endocr Rev       Date:  2002-06       Impact factor: 19.871

7.  Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Authors:  M Dror Michaelson; Donald S Kaufman; Hang Lee; Francis J McGovern; Philip W Kantoff; Mary Anne Fallon; Joel S Finkelstein; Matthew R Smith
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

8.  Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects.

Authors:  G Graziani; G Como; S Badalamenti; S Finazzi; A Malesci; M Gallieni; D Brancaccio; C Ponticelli
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

9.  Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures.

Authors:  B Ettinger; A Pressman; P Sklarin; D C Bauer; J A Cauley; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958

10.  Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.

Authors:  Matthew R Smith; Mary Anne Fallon; Hang Lee; Joel S Finkelstein
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

View more
  23 in total

1.  Relationship between bone cross-sectional area and indices of peripheral artery disease.

Authors:  Claudio Pedone; Simone Scarlata; Nicola Napoli; Fulvio Lauretani; Stefania Bandinelli; Luigi Ferrucci; Raffaele Antonelli Incalzi
Journal:  Calcif Tissue Int       Date:  2013-09-01       Impact factor: 4.333

2.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

3.  Premature discard of proton pump inhibitors: possible osteoporosis vs enhanced gastrointestinal bleed, adenocarcinoma efficacy.

Authors:  Aaron S Geller
Journal:  Mayo Clin Proc       Date:  2011-09       Impact factor: 7.616

4.  Antiretroviral therapy and adverse skeletal effects.

Authors:  Gianluigi Fabbriciani; Giuseppe V L De Socio; Marco Massarotti
Journal:  Mayo Clin Proc       Date:  2011-09       Impact factor: 7.616

5.  Are selective serotonin reuptake inhibitors associated with fractures?

Authors:  Sarah Drost; Anne Massicotte
Journal:  Can Pharm J (Ott)       Date:  2016-10-06

Review 6.  The Impact of Psychotropic Medications on Bone Health in Youth.

Authors:  Jessie N Rice; Carrie B Gillett; Nasuh M Malas
Journal:  Curr Psychiatry Rep       Date:  2018-09-24       Impact factor: 5.285

7.  Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases.

Authors:  Quentin Dardonville; Esther Salguiero; Vanessa Rousseau; Leila Chebane; Jean Luc Faillie; Sophie Gautier; Jean Louis Montastruc; Alfonso Carvajal; Haleh Bagheri
Journal:  Eur J Clin Pharmacol       Date:  2019-08-29       Impact factor: 2.953

8.  SSRIs: bad to the bone?

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2012-07

Review 9.  [Immunosuppressive treatment and bone healing].

Authors:  Dagmar Horn; Christoph Klaas; Michael Raschke; Richard Stange
Journal:  Unfallchirurg       Date:  2019-07       Impact factor: 1.000

Review 10.  Neuroendocrine considerations in the treatment of men and women with epilepsy.

Authors:  Cynthia L Harden; Page B Pennell
Journal:  Lancet Neurol       Date:  2013-01       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.